Primary Menu

Skip to content
Lycera
  • About Us
    • Corporate Overview
    • Management Team
    • Board of Directors
    • Expanded Access
  • Programs
    • LYC-55716
    • ATPase Modulators
    • New IO Targets
  • Pipeline
  • Investors
    • Investors
    • Investor FAQ’s
    • Contact Us
  • News & Events
    • Press Releases
    • Lycera in the News
  • Careers
    • Contact Us

Lycera in the News

Agonizing Cancer Immunotherapy

  Feb 23, 2015    BioCentury

Endogenous agonists for orphan RORγ

  Jan 23, 2015    Nature Immunology Reviews

Lycera Enters Into Second Collaboration Deal with Merck

  Mar 7, 2013    Xconomy

Merck ups autoimmune prize to $600M for small Michigan biotech

  Mar 7, 2013    FierceBiotech

Lycera snags $307M anti-inflammatory discovery Deal with Merck

  Mar 3, 2011    FierceBiotech

Targeting T cell metabolism

  Mar 3, 2011    SciBx

Lycera Plows Ahead With Drugs To Treat Autoimmune Disorders

  Feb 24, 2011    Xconomy

paging-navigation

Footer Menu

  • Contact Us

Social Media Menu

  • LinkedIn
© 2022 Lycera - website by ZURNET